Department of Hepatobillary Surgery, General Hospital of Chinese People's Liberation Army, Beijing 100853, China.
Chin Med J (Engl). 2012 Jan;125(2):197-202.
This retrospective study was undertaken to analyze the outcome of hepatic resection in fifty-two patients with unresectable hepatocellular carcinoma (HCC) between January 2004 and December 2008.
Among these fifty-two patients, the mean diameter of the tumor was 7.9 cm (4.4 - 15.5 cm, median 8.5 cm) prior to the first transcatheter arterial chemoembolization (TACE). After 1 - 6 times of TACE (median 2), the median tumor diameter was reduced to 4.2 cm (0 - 8.4 cm) prior to resection. The duration between the last TACE treatment and sequential resection varied from one to six months (median 2.7 months). Serum a-fetoprotein (AFP) levels were abnormal in thirty-eight out of the fifty-two patients. In AFP producing HCCs, AFP levels returned to normal (≤ 400 µg/L) in twenty-five out of thirty-eight patients. Hepatic segmentectomy, multiple hepatic segmentectomy or partial hepatic resection were performed in forty-five patients, two underwent extended left hemihepatectomy, and one underwent right posterior branch portal vein thrombectomy. One patient received a right hemihepatectomy and three had left hemihepatectomies.
Complete tumor radiological response (CR) occurred in five patients (9.6%). There were three cases of perioperative mortality in the fifty-two patients (5.8%). One patient underwent salvaged orthotopic liver transplantation, and twenty-one patients observed tumor recurrence within two years. The 1-, 3- and 5-year survival rates of the fifty-two patients were 77.0% (n = 40), 55.0% (n = 29), and 52.0% (n = 28), respectively. The median survival time after surgery was 49 months (95% confidence interval 7.5 - 52.7 months).
TACE treatment provides a better chance for HCC resection in patients initially diagnosed with unresectable HCC. Furthermore, liver resection should be performed once the tumor is downstaged to be compatible for successful resection.
本回顾性研究分析了 2004 年 1 月至 2008 年 12 月期间 52 例不能切除的肝细胞癌(HCC)患者行肝切除术的结果。
这 52 例患者中,首次经导管肝动脉化疗栓塞(TACE)前肿瘤的平均直径为 7.9cm(4.4-15.5cm,中位数 8.5cm)。在 1-6 次 TACE(中位数 2 次)后,在切除前肿瘤的中位数直径缩小至 4.2cm(0-8.4cm)。最后一次 TACE 治疗与序贯切除之间的时间间隔为 1-6 个月(中位数 2.7 个月)。52 例患者中有 38 例血清甲胎蛋白(AFP)异常。在 AFP 产生的 HCC 中,38 例中有 25 例 AFP 水平恢复正常(≤400μg/L)。45 例患者行肝段切除术、多肝段切除术或部分肝切除术,2 例行扩大左半肝切除术,1 例行右后支门静脉血栓切除术。1 例患者行右半肝切除术,3 例行左半肝切除术。
5 例(9.6%)患者完全肿瘤影像学反应(CR)。52 例患者中有 3 例围手术期死亡(5.8%)。1 例患者接受了挽救性原位肝移植,21 例患者在 2 年内观察到肿瘤复发。52 例患者的 1 年、3 年和 5 年生存率分别为 77.0%(n=40)、55.0%(n=29)和 52.0%(n=28)。术后中位生存时间为 49 个月(95%置信区间 7.5-52.7 个月)。
TACE 治疗为最初诊断为不可切除 HCC 的患者提供了更好的 HCC 切除机会。此外,一旦肿瘤降期至适合成功切除,应进行肝切除术。